Clinical Trials Browser

Phase 1/2 × NIH × Capecitabine × Clear all

NCT05849480 2026-03-24

A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)

Phase 1/2 Recruiting

Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms

NCT00121251 2021-04-06

Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer

Phase 1/2 Completed

17 enrolled 13 charts

Carcinoma, Renal Cell

NCT00070252 2015-05-04

Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer

Phase 1/2 Completed

Breast Neoplasms, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

NCT00021047 2012-03-08

Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor

Phase 1/2 Completed

CNSGastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Bile Duct Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Esthesioneuroblastoma, Olfactory

NCT00496704 2009-08-21

Gemcitabine, Capecitabine, and Oxaliplatin as Second-Line Therapy in Treating Patients With Advanced Colorectal Cancer Previously Treated With Irinotecan

Phase 1/2 Unknown

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms